Prevalence of measles antibodies among migrant workers in Singapore: a serological study to identify susceptible population subgroups

Li Wei Ang1,2*, Qi Gao1†, Lin Cui3, Aysha Farwin1, Matthias Paul Han Sim Toh1,4, Irving Charles Boudville1, Mark I-Cheng Chen1,2, Angela Chow1,4,5,6, Raymond Tzer-Pin Lin3,7,8, Vernon Jian Ming Lee3,4† and Yee Sin Leo4,5,7,9,10†

Abstract

Background: In 2019, two clusters of measles cases were reported in migrant worker dormitories in Singapore. We conducted a seroprevalence study to measure the level of susceptibility to measles among migrant workers in Singapore.

Methods: Our study involved residual sera of migrant workers from seven Asian countries (Bangladesh, China, India, Indonesia, Malaysia, Myanmar and the Philippines) who had participated in a survey between 2016 and 2019. Immunoglobulin G (IgG) antibody levels were first measured using a commercial enzyme-linked immunosorbent assay (ELISA) test kit. Those with equivocal or negative IgG results were further evaluated using plaque reduction neutralization test (PRNT).

Results: A total of 2234 migrant workers aged 20–49 years were included in the study. The overall prevalence of measles IgG antibodies among migrant workers from the seven Asian countries was 90.5% (95% confidence interval 89.2–91.6%). The country-specific seroprevalence ranged from 80.3 to 94.0%. The seroprevalence was significantly higher among migrant workers born in 1965–1989 than those born in 1990–1999 (95.3% vs. 86.6%, $p < 0.0005$), whereas there was no significant difference by gender (90.8% in men vs. 89.9% in women, $p = 0.508$). 195 out of 213 samples with equivocal or negative ELISA results were tested positive using PRNT.

Conclusion: The IgG seroprevalence in migrant workers was below the herd immunity threshold of 95% for measles. Sporadic outbreaks may occur in susceptible individuals due to high transmissibility of measles virus. Seroprevalence surveys can help identify susceptible subgroups for vaccination.

Keywords: Measles, Immunity, Prevalence, Vaccination coverage, Migrant workers
elimination goal, but there is considerable variation in vaccination coverage by region and country [1]. The global resurgence of measles in 2018 and 2019 has highlighted the urgent need for renewed focus on measles vaccination efforts, particularly in population subgroups with suboptimal vaccination coverage [2].

The foreign workforce made up about a quarter of Singapore’s population of 5.69 million people in 2020, including 0.85 million on work permits who mainly engage in semi-skilled work [3]. The annual incidence of measles in Singapore ranged from 3 to 29 per million population during the 10-year period from 2009 to 2018 (Additional file 1: Fig. S1) [4]. Measles vaccination was made compulsory for children under the National Childhood Immunization Program in 1985 [5]. Since 2011, the measles, mumps and rubella (MMR) immunization schedule has consisted of the first dose at 12 months and the second dose at 15–18 months of age [6]. The two-dose MMR vaccination coverage ranged from 88 to 92% in Singapore residents at 2 years of age from 2013 to 2018 [7]. The high population immunity among Singapore residents is well demonstrated by serological surveys with measles prevalence of 98% in those aged 1–17 years in 2018 [8] and over 95% in adults in 2004 [9]. However, the immunity level against measles among non-residents in Singapore is unknown, particularly in vulnerable population groups who may require catch-up vaccination.

In 2019, two measles outbreaks involving six cases each were reported in two migrant worker dormitories in Singapore from 14 to 27 June and from 9 to 29 July, respectively [10]. One cluster comprised four cases from Bangladesh and two from India, and the other cluster comprised five cases from Bangladesh and one from India [10]. The median age of measles cases in each cluster was 30 years [10]. As their childhood vaccination and serology status was unknown, an added measure to minimise the risk of further transmission through ring vaccination was initiated for all close contacts of the measles cases who did not have proof of vaccination or immunity [10]. Such measles outbreak occurrences in densely populated dormitories stress the importance of profiling the prevalence of measles antibodies among migrant workers for an accurate assessment of their immunity status.

We conducted a serological study to assess the level of susceptibility to measles among migrant workers in Singapore. The findings will provide guidance for planning outbreak prevention and control programmes in the migrant worker population.

**Methods**

**Seroprevalence survey**

The measles seroprevalence study was conducted in accordance with the Infectious Diseases Act [11] which provides for the use of residual blood samples for the purpose of public health surveillance.

The study involved residual sera collected between 2016 and 2019 from a survey on latent tuberculosis among 3584 migrant workers in Singapore from eight Asian countries with large number of migrant workers in Singapore (Bangladesh, China, India, Indonesia, Malaysia, Myanmar, the Philippines and Vietnam). They were recruited from 27 locations around Singapore [12]. About 67% were recruited from clinics providing health screening services for migrant workers, 30% from migrant worker dormitories and 3% from recreation centres catering to migrant workers. The inclusion criteria were: (1) aged 20–50 years; (2) no previous employment in Singapore; (3) stayed in Singapore for less than a year.

Migrant workers who participated in the survey on latent tuberculosis and provided consent for their data and residual sera to be used for future research were eligible for inclusion in our study. For this serological study, the minimum sample size for each country of origin and birth cohort was determined based on published reports of measles seroprevalence in Bangladesh [13], China [14], India [15] and Malaysia [16] (Additional file 1: Table S1) with a confidence level of 95% and relative precision of 5%. For migrant workers from Indonesia, Myanmar and the Philippines, we assumed their measles antibody prevalence was at least 85% in each birth cohort, which gave a minimum sample size of 272 with a confidence level of 95% and relative precision of 5%. We used random sampling to select migrant workers from each country of origin and birth cohort if the number of available residual sera exceeded the minimum sample size required. We excluded migrant workers from Vietnam from the analysis as there were only 15 residual sera available in total.

**Measurement of measles antibodies**

Testing of the residual sera was conducted by the National Public Health Laboratory, the national reference laboratory for measles in Singapore. Immunoglobulin G (IgG) antibody levels were measured using an enzyme-linked immunosorbent assay (ELISA), Enzygnost® Anti-Measles Virus/IgG (Siemens, Germany). Test results were reported in corrected optical density (ΔOD) and classified into three categories according to the manufacturer’s instructions: negative (ΔOD < 0.1), equivocal (0.1 ≤ ΔOD ≤ 0.2) or positive (ΔOD > 0.2).

Plaque reduction neutralization test (PRNT) is known as the gold standard assay for evaluation of humoral immunity to measles [17, 18]. Samples with equivocal and negative ELISA results were further evaluated using PRNT. The assay was adopted from a standardized laboratory protocol for measles PRNT by the WHO which was subsequently validated for use in clinical trials.
of aerosolized measles vaccines [19]. The measles PRNT titre was calculated from the dilution that reduced the number of plaques by 50%, and a value $\geq 8$ was considered positive.

Statistical analysis
We used the Wilson method [20] to compute the 95% confidence intervals (CI) for binomial proportions. The Mantel–Haenszel chi-square test for trend was used to evaluate the difference in seroprevalence across age groups. Fisher’s exact test was used to test for differences in seroprevalence by gender. All analyses were performed using SPSS version 24 (IBM, USA). All $p$ values reported were 2-sided and statistical significance was taken as $p<0.05$.

Results
A total of 2234 migrant workers with residual sera were included in the study. Their mean age was 27.3 years (standard deviation 5.1, range 20–49). Among them, 30.4% were from India, 20.1% from Indonesia, 12.9% from Bangladesh, 12.7% from Myanmar and the remaining were from China, the Philippines and Malaysia (Table 1). All migrant workers from Bangladesh and more than 94% from China, India and Malaysia were men. All except one from Indonesia, 94.1% from the Philippines and 83.5% from Myanmar were women.

The overall prevalence of measles IgG antibodies among the migrant workers from the seven Asian countries was 90.5% (95% confidence interval [CI] 89.2–91.6%). The seroprevalence was above 80% in migrant workers from each country of origin (Fig. 1).

Table 1 Number of migrant workers included in study by country of origin, birth cohort and gender

| Country of origin | Bangladesh | China | India | Indonesia | Malaysia | Myanmar | Philippines |
|-------------------|------------|-------|-------|-----------|----------|---------|-------------|
| Total             | 289        | 193   | 679   | 450       | 152      | 284     | 187         |
| Birth cohort      |            |       |       |           |          |         |             |
| 1965–1984         | 31         | 72    | 101   | 137       | 18       | 24      | 64          |
| 1985–1989         | 63         | 67    | 171   | 104       | 24       | 48      | 64          |
| 1990–1994         | 136        | 43    | 205   | 209       | 64       | 207     | 59          |
| 1995–1999         | 59         | 11    | 202   | 0         | 46       | 5       | 0           |
| Gender            |            |       |       |           |          |         |             |
| Male              | 289        | 182   | 668   | 1         | 143      | 47      | 11          |
| Female            | 0          | 11    | 11    | 449       | 9        | 237     | 176         |

Fig. 1 Measles IgG seroprevalence (%) measured by ELISA among migrant workers in Singapore by country of origin. The error bars indicate 95% confidence interval (CI)
The seroprevalence ranged from 80.3% in workers from Malaysia to 94.0% from Indonesia. The country-specific seroprevalence was above 85% among workers born in 1965–1984 and those born in 1985–1989, and it exceeded 72% for both men and women (Table 2). When aggregated across the seven countries, the prevalence of measles IgG antibodies was significantly higher in migrant workers born in 1965–1989 than those born in 1990–1999 (95.3% vs. 86.6%, \(p < 0.0005\)), whereas there was no significant difference by gender (90.8% in men vs. 89.9% in women, \(p = 0.508\)).

There were 213 samples with equivocal or negative ELISA results. Among these, 195 (91.5%) tested positive using PRNT. Of 116 IgG-equivocal and 97 IgG-negative, 115 (99.1%) and 80 (82.5%) tested positive using PRNT, respectively.

**Discussion**

In our serological study, the overall IgG seroprevalence of measles in migrant workers from all the seven Asian countries was below the herd immunity threshold of 95% for measles [21]. Sporadic measles outbreaks can occur in susceptible individuals, particularly in those originating from countries with suboptimal vaccination coverage. The high transmissibility of measles virus and close living environments of migrant worker dormitories may have led to the two clusters of measles cases reported in 2019 in Singapore. There have been reports of measles outbreaks associated with vaccine failure or low vaccine effectiveness in other countries [22–24].

In this study, the IgG seroprevalence was significantly higher among older migrant workers born in 1989 and earlier years. The age at vaccination is an important host factor in determining the immune response to measles-containing vaccine (MCV) [25]. Most studies on the immunogenicity of standard-titre MCV did not report on gender differences in seroconversion rates [25].

Measles is endemic in all the seven Asian countries where the migrant workers hailed from [26]. The humoral immunity against measles observed in migrant workers is more likely to be due to past infection for those born before or in the first few years when childhood measles vaccination was introduced in the countries where they hailed from. In 1995, the vaccination coverage of the first dose for measles in children aged ≤1 year ranged from 72% in India to 86% in Malaysia (Additional file 1: Table S2). More than two decades later, the measles vaccination coverage of the first dose in 2019 increased in all these countries except in the Philippines [27–34] (Additional file 1: Table S2).

Upon arrival in Singapore, all migrant workers have to undergo a pre-employment health examination, which includes review of medical history, physical examination and screening, and subsequent screening [35]. There is no vaccination policy against infectious diseases such as measles for migrant workers. The measles seroprevalence of migrant workers observed in our study could be due to a combination of those with vaccine-derived and naturally acquired immunity [10].

In 2018, Singapore was verified as having achieved measles elimination by the WHO [36, 37]. However, Singapore still faces the risk of measles importations from international travellers and migrant workers [36]. The measles outbreaks in 2019 have prompted an evaluation of the need for a catch-up vaccination program for all migrant workers without documentation of receipt of two doses of MMR. Given the highly contagious nature of measles virus, a multi-pronged approach remains essential in minimizing the risk of disease transmission. Atypical clinical presentations, especially among those who have immunity to measles [38–41], pose a challenge to early detection of cases. Hence it is important to remain vigilant, conduct thorough epidemiological investigation of suspected cases,

| Country of origin | Bangladesh | China | India | Indonesia | Malaysia | Myanmar | Philippines |
|-------------------|------------|-------|-------|-----------|----------|---------|------------|
| Birth cohort      |            |       |       |           |          |         |            |
| 1965–1984         | 100 (89.0–100) | 91.7 (83.0–96.1) | 99.0 (94.6–99.8) | 97.8 (93.8–99.3) | 88.9 (67.2–96.9) | 100 (86.2–100) | 96.9 (89.3–99.1) |
| 1985–1989         | 98.4 (91.5–99.7) | 88.1 (78.2–93.8) | 97.1 (93.3–98.7) | 96.2 (90.5–98.5) | 87.5 (69.0–95.7) | 93.8 (83.2–97.9) | 87.5 (77.2–93.5) |
| 1990–1994         | 91.9 (86.1–95.4) | 93.0 (81.4–97.6) | 91.7 (87.1–94.8) | 90.4 (85.7–93.7) | 79.7 (68.3–87.7) | 77.3 (71.1–82.5) | 84.7 (73.5–91.8) |
| 1995–1999         | 84.7 (73.5–91.8) | 100 (74.1–100) | 88.1 (82.9–91.9) | 73.9 (59.7–84.4) | 60.0 (23.1–88.2) | –          | –          |
| Gender            |            |       |       |           |          |         |            |
| Male              | 92.7 (89.1–95.2) | 92.3 (87.5–95.4) | 93.1 (90.9–94.8) | 100 (20.7–100) | 79.0 (71.6–84.9) | 76.6 (62.8–86.4) | 90.9 (62.3–98.4) |
| Female            | –            | 72.7 (43.4–90.3) | 90.9 (62.3–98.4) | 94.0 (91.4–95.8) | 100 (70.1–100) | 82.7 (77.4–87.0) | 89.8 (84.4–93.4) |
obtain respiratory samples to perform polymerase chain reaction tests and genotyping for these cases, and implement prevention and control measures despite high seroprevalence of measles in migrant workers [10]. Approximately 82.5% of the 97 samples which had been tested IgG-negative and all except one of 116 samples tested IgG-equivocal using ELISA were found to be seropositive after subsequent PRNT. If positive PRNT results were included in the classification of results, the country-specific measles seropositivity of migrant workers would have ranged from 97.9 to 100% instead of from 80.3 to 94.0% based on ELISA alone (Additional file 1: Table S3). It is not known whether the antibody levels of individuals who tested ELISA negative but PRNT positive correlate with protection against measles, and this should be determined by long-term follow-up.

As this study was based on residual sera from a survey on latent tuberculosis, and there was no published data on distribution of migrant workers by country of origin and age group in Singapore, we were unable to assess whether the study sample was representative of the migrant workers at large. The small number of migrant workers in some age groups limited the comparison by birth cohort and led to wide confidence intervals of the seroprevalence estimates.

Conclusions
The IgG seroprevalence in migrant workers from each of the seven Asian countries was below the herd immunity threshold of 95% for measles. This study underscores the importance of periodic seroprevalence surveys to measure the level of immunity against measles in migrant workers, so as to identify susceptible subgroups for active vaccination.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07066-2.

Additional file 1: Figure S1. Annual incidence of reported measles cases in Singapore, 2000–2018. Table S1. Seroprevalence of measles IgG antibodies in Bangladesh, China, India and Malaysia. Table S2. Vaccination schedule and vaccination coverage for measles, and incidence per million population of measles cases in Bangladesh, China, India, Indonesia, Malaysia, Myanmar and the Philippines. Table S3. Number and percentage of samples tested positive based on ELISA alone and those based on ELISA or PRNT by country of origin, birth cohort and gender.

Acknowledgements
We thank the migrant workers who participated in the survey on latent tuberculosis in Singapore. We also thank Pei Ling Loh, Tom Yen, Sarah Tan, Winston Lee and Yu Ling Ho for performing the laboratory tests and supporting logistical arrangements.

Authors’ contributions
VJML and YSL initiated the study and MICC designed the research. LWA analyzed and interpreted the data. LWA and QG drafted the manuscript. LC, AF, MPHST, ICB, MICC, AC, RTPL, VJML and YSL reviewed the manuscript. All authors read and approved the final manuscript.

Funding
Sample collection was supported by the Ministry of Health, Singapore, under the Communicable Diseases—Public Health Research Grant (Grant Number MOHCS1SMA001). Laboratory testing for the seroprevalence of measles in migrant workers was supported by the National Public Health Laboratory.

Availability of data and materials
The data that support the findings of this study are available from Qi Gao, National Public Health and Epidemiology Unit, but restrictions apply to the availability of the data, which was used under license for the current study, and so are not publicly available. Data are however available from Qi Gao upon reasonable request.

Declarations
Ethics approval and consent to participate
The study does not require ethical approval and consent to participate as it was conducted in accordance with section 7 of the Infectious Diseases Act in Singapore pertaining to provision for public health surveillance using residual samples (https://sso.agc.gov.sg/Act/IDA1976/Provids=PIII#pr7). The study involved only residual blood samples from participants of a survey on latent tuberculosis who had provided consent for their data and residual sera to be used for future research. All methods were carried out in accordance with relevant guidelines and regulations. Analyses were performed on an anonymized dataset.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 National Public Health and Epidemiology Unit, National Centre for Infectious Diseases, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore. 2 Public Health Group, Ministry of Health, Singapore, Singapore. 3 National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore. 4 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 5 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. 6 Department of Clinical Epidemiology, Office of Clinical Epidemiology, Analytics, and Knowledge (OCEAN), Tan Tock Seng Hospital, Singapore, Singapore. 7 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 8 Department of Laboratory Medicine, National University Hospital, National University Health System, Singapore, Singapore. 9 National Centre for Infectious Diseases, Singapore, Singapore. 10 Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.

Received: 6 July 2021 Accepted: 13 January 2022
Published online: 25 January 2022

References
1. Strategic Advisory Group of Experts on Immunization. The global vaccine action plan 2011–2020. Review and lessons learned. Geneva: World Health Organization; 2019 (WHO/V8/19.07). Available at: https://apps.who.int/iris/handle/10665/329097. Accessed 24 Nov 2020.
2. Durrheim DN. Measles eradication—retreating is not an option. Lancet Infect Dis. 2020;20(6):e138–41. https://doi.org/10.1016/S1473-3099(20)30052-9.
3. Ministry of Manpower, Singapore. Foreign workforce numbers. Available at: http://www.mom.gov.sg/documents-and-publications/foreign-workforce-numbers. Accessed 8 Apr 2021.
4. Ministry of Health, Singapore. Communicable diseases surveillance in Singapore 2018. Available at: https://www.moh.gov.sg/resources-statistics/reports/communicable-diseases-surveillance-in-singapore-2018. Accessed 24 Nov 2020.

5. Liew F, Ang LW, Cutter J, James L, Goh KT. Evaluation on the effectiveness of the national childhood immunisation programme in Singapore, 1982–2007. Ann Acad Med Singap. 2010;39(7):532–10.

6. Ministry of Health, Singapore. National childhood immunisation schedule. Available at: https://www.moh.gov.sg/resources-statistics/nationally-recommended-vaccines. Accessed 3 Apr 2021.

7. Ministry of Health, Singapore. Communicable diseases surveillance in Singapore 2018. Available at: https://www.moh.gov.sg/docs/librariesprovider5/diseases-updates/communicable-diseases-surveillance-in-singapore-2018210c9a3beaa4db49229b2da35322dce.pdf. Accessed 3 Apr 2021.

8. Ng Y, Chua LAV, Cui L, Ang LW, Tee NWS, Lin RTP, et al. Seroprevalence of vaccine-preventable diseases among children and adolescents in Singapore: results from the National Paediatric Seroprevalence Survey 2018. Int J Infect Dis. 2020;202:234–40. https://doi.org/10.1016/j.ijid.2019.12.015.

9. Ho HJ, Low C, Ang LW, Cutter JL, Tay J, Chan KP, et al. Progress towards measles elimination in Singapore. Vaccine. 2014;32(5):6927–33. https://doi.org/10.1016/j.vaccine.2014.01.046.

10. Pung R, Lee TH, Peh X, Cui L, Poh C, Low C, et al. Measles ring vaccination in dormitories: an outbreak containment measure and simulation study. Preprint available at SSRN. https://doi.org/10.21239/03502369. Accessed 13 June 2021.

11. Ministry of Health, Singapore. Infectious Diseases Act. https://www.moh.gov.sg/policies-and-legislation/infectious-diseases­act. Accessed 8 Dec 2020.

12. Lim VW, Wee HL, Lee P, Lin Y, Tan YR, Tan MX, et al. Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore. BMJ Open. 2021;11(7):e050629. https://doi.org/10.1136/bmjopen-2021-050629.

13. Hayford KT, Shomik MS, Al-Emran HM, Moss WJ, Bishai D, Levine OS. Measles immunogenicity of measles vaccination. Vaccine. 2008;26(50):6392–7. https://doi.org/10.1016/j.vaccine.2008.07.074.

14. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccines. Vaccine. 2008;26(50):6392–7. https://doi.org/10.1016/j.vaccine.2008.07.074.

15. Cohen BJ, Audet S, Andrews N, Beeler J. WHO working group on measles plaque reduction neutralization test. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007;26(1):59–66. https://doi.org/10.1016/j.vaccine.2007.10.046.

16. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–12. https://doi.org/10.1080/01621459.1927.10502953.

17. World Health Organization. Manual for the laboratory-based surveillance of measles, rubella and congenital rubella syndrome, June, 2018. Available at: https://apps.who.int/iris/handle/10665/331533. Accessed 24 Sept 2021.

18. WHO, Western Pacific Region. Singapore writes out measles; Australia, Brunei Darussalam and Macao SAR (China) eliminate rubella. Available at: https://www.who.int/westernpacific/news/detail/31-10-2018-singapore-writes-out-measles-australia-brunei-darussalam-and-macao-sar-china-rubella-elimination?r=nc0&Lang=en. Accessed 7 Apr 2021.

19. Cohen BJ, Audet S, Andrews N, Beeler J. WHO working group on measles plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccines. Vaccine. 2008;26(50):6392–7. https://doi.org/10.1016/j.vaccine.2008.07.074.

20. WHO. The immunological basis for vaccination series: module 7: measles. Update 2020. Geneva. World Health Organization. 2020. Available at: https://apps.who.int/iris/handle/10665/331533. Accessed 24 Sept 2021.

21. Ministry of Health, Republic of the Philippines. Expanded programme on immunization. Available at: https://doh.gov.ph/expanded-program-on-immunization. Accessed 3 Apr 2021.

22. Department Of Health, Ministry Of Health, Malaysia. Available at: https://www.fondation-merieux.org/wp-content/uploads/2017/10/vaccinology-2017-fairadh-kusnin.pdf. Accessed 3 Apr 2021.

23. Department Of Health & Family Welfare, Government Of Himachal Pradesh, India. Universal immunization programme. Available at: http://www.nrhmhp.gov.in/content/immunization. Accessed 3 Apr 2021.

24. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Indonesia. Available at: https://www.who.int/docs/default-source/indonesia/indonesia-epi-factsheet-2019.pdf?fbvsrc=91c1f182_2. Accessed 3 Apr 2021.

25. WHO. The immunological basis for immunization series: module 7: measles. Update 2020. Geneva. World Health Organization. 2020. Available at: https://apps.who.int/iris/handle/10665/331533. Accessed 24 Sept 2021.

26. Department Of Health & Family Welfare, Government Of Himachal Pradesh, India. Universal immunization programme. Available at: http://www.nrhmhp.gov.in/content/immunization. Accessed 3 Apr 2021.

27. Department Of Health, Ministry Of Health, Malaysia. Available at: https://www.fondation-merieux.org/wp-content/uploads/2017/10/vaccinology-2017-fairadh-kusnin.pdf. Accessed 3 Apr 2021.

28. Department Of Health & Family Welfare, Government Of Himachal Pradesh, India. Universal immunization programme. Available at: http://www.nrhmhp.gov.in/content/immunization. Accessed 3 Apr 2021.

29. Expanded programme on immunisation (EPI) factsheet 2019: Indonesia. Available at: https://www.who.int/docs/default-source/indonesia/indonesia-epi-factsheet-2019.pdf?fbvsrc=91c1f182_2. Accessed 3 Apr 2021.

30. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.

31. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.

32. Department Of Health, Ministry Of Health, Malaysia. Available at: https://www.fondation-merieux.org/wp-content/uploads/2017/10/vaccinology-2017-fairadh-kusnin.pdf. Accessed 3 Apr 2021.

33. Department Of Health & Family Welfare, Government Of Himachal Pradesh, India. Universal immunization programme. Available at: http://www.nrhmhp.gov.in/content/immunization. Accessed 3 Apr 2021.

34. Expanded programme on immunisation (EPI) factsheet 2019: Indonesia. Available at: https://www.who.int/docs/default-source/indonesia/indonesia-epi-factsheet-2019.pdf?fbvsrc=91c1f182_2. Accessed 3 Apr 2021.

35. The Immunological basis for immunization series: module 7: measles. Update 2020. Geneva. World Health Organization. 2020. Available at: https://apps.who.int/iris/handle/10665/331533. Accessed 24 Sept 2021.

36. Department Of Health & Family Welfare, Government Of Himachal Pradesh, India. Universal immunization programme. Available at: http://www.nrhmhp.gov.in/content/immunization. Accessed 3 Apr 2021.

37. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.

38. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.

39. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.

40. Immunisation And Vaccine Development South-East Asian Region, WHO. Expanded programme on immunisation (EPI) factsheet 2019: Myanmar. Available at: https://apps.who.int/iris/bitstream/handle/10665/329987/Myanmar2019_epi-pdf/sequence=1&isAllowed=y. Accessed 3 Apr 2021.
2017. MMWR Morb Mortal Wkly Rep. 2018;67(42):1186–8. https://doi.org/10.15585/mmwr.mm6742a4.

41. Cornelissen L, Grammens T, Leenen S, Schirvel C, Hutse V, Demeester R, et al. High number of hospitalisations and non-classical presentations: lessons learned from a measles outbreak in 2017, Belgium. Epidemiol Infect. 2020;148: e35. https://doi.org/10.1017/S0950268820000278.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.